Table 1.
Characteristics and outcome of patients with SARS-CoV-2 infection stratified by vaccination status
| Unvaccinated | First dose | Second dose | Third dose | Total | ||
|---|---|---|---|---|---|---|
| N | 200 | 56 | 433 | 437 | 1126 | |
| Days post dose, median(IQR) | 293 (158–344) | 252 (220–270) | 64 (51–80) | |||
| Age, median(IQR) | 55 (44–64) | 62 (45–73) | 60 (50–72) | 64 (54–75) | 61 (50–73) | |
| Gender | Male | 100 (50) | 34 (61) | 251 (58) | 282 (65) | 667 (59) |
| Ethnicity | Asian/other | 44 (22) | 20 (36) | 141 (33) | 186 (43) | 391 (35) |
| Black | 119 (59) | 27 (48) | 180 (42) | 128 (29) | 454 (40) | |
| White | 37 (19) | 9 (16) | 112 (26) | 123 (28) | 281 (25) | |
| Diabetes | 77 (39) | 24 (43) | 206 (48) | 202 (46) | 509 (45) | |
| Immune suppressiona | 31 (16) | 8 (14) | 74 (17) | 72 (16) | 185 (16) | |
| Prior SARS-CoV-2b | 40 (20) | 12 (21) | 67 (15) | 69 (16) | 188 (17) | |
| Outcome | Admissionc | 39 (20) | 9 (16) | 69 (16) | 43 (10) | 160 (14) |
| Oxygend | 19 (10) | 5 (9) | 35 (8) | 24 (5) | 83 (7) | |
| Ventilationd | 7 (4) | 3 (5) | 18 (4) | 9 (2) | 37 (3) | |
| Deathd | 5 (3) | 2 (4) | 14 (3) | 7 (2) | 28 (2) |
Except where stated data are N (%).
Clinical outcomes are ‘all cause’, not specifically due to Covid-19.
Vaccination status considered to change after the 7th post dose day.
a
Any immune suppression treatment including steroids, tacrolimus, mycophenolate, azathioprine, cytotoxic and biologic agents.
b
PCR positive at least 90 days prior to the current infection.
c
Within 14 days of positive PCR.
d
Within 28 days of positive PCR.